Delving into the Latest Updates on Hunan Jiaheng Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1

主要研究目的评价中国健康男性受试者空腹及餐后条件下单次单剂量口服他达拉非片受试制剂（规格：20 mg，持有人：湖南嘉恒制药有限公司）和参比制剂希爱力®（规格：20 mg，持证商：Eli Lilly Nederland B.V.）后的药代动力学特点和生物等效性。次要研究目的研究受试制剂他达拉非片（规格：20 mg）和参比制剂希爱力®（规格：20 mg）在健康受试者中的安全性。

[Translation]

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of tadalafil tablets (specification: 20 mg, holder: Hunan Jiaheng Pharmaceutical Co., Ltd.) and the reference formulation Cialis® (specification: 20 mg, licensee: Eli Lilly Nederland B.V.) after a single oral dose in healthy Chinese male subjects under fasting and postprandial conditions. Secondary study objectives To study the safety of the test formulation of tadalafil tablets (specification: 20 mg) and the reference formulation Cialis® (specification: 20 mg) in healthy subjects.

Start Date-

Sponsor / Collaborator

Hunan Jiaheng Pharmaceutical Co., Ltd.

100 Clinical Results associated with Hunan Jiaheng Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hunan Jiaheng Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Hunan Jiaheng Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hunan Jiaheng Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Login to view more data